One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity

Pharmacogenomics. 2016 Jun;17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1.

Authors

Daniel L Hertz¹, James M Rae²

Affiliations

¹ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
² Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

PMID: 27249031
DOI: 10.2217/pgs-2016-0059

No abstract available

Keywords: CYP2D6; clinical utility; clinical validity; endoxifen; estrogen receptor positive breast cancer; tamoxifen.

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Cytochrome P-450 CYP2D6 / genetics*
Female
Genotype
Humans
Tamoxifen / adverse effects
Tamoxifen / analogs & derivatives
Tamoxifen / therapeutic use*

Substances

Tamoxifen
4-hydroxy-N-desmethyltamoxifen
Cytochrome P-450 CYP2D6